This site uses cookies. By continuing, your consent is assumed. Learn more

125.1fm shares

Peginesatide fdating

opinion

Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants TCAs. Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in Peginesatide fdating it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder depressive neurosis and major depressive Peginesatide fdating.

Peginesatide for maintenance treatment of...

Maprotiline is effective at reducing symptoms of anxiety associated with depression. For treatment of depression, Peginesatide fdating the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis. Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression.

Peginesatide fdating one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase.

Maprotiline is a strong inhibitor of noradrenaline reuptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, Peginesatide fdating displays strong antihistaminic action which may explain its sedative effects as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline. Maprotiline exerts its antidepressant action by inhibition of presynaptic uptake of catecholamines, thereby increasing their concentration at the synaptic clefts of the brain.

In single doses, the effect of maprotiline on the EEG revealed a rise in the alpha-wave density, a reduction Peginesatide fdating the alpha-wave frequency and an increase in the alpha-wave amplitude.

However, as with other tricyclic antidepressants, maprotiline lowers the convulsive threshold. Maprotiline also inhibits the amine transporter, delaying the reuptake of noradrenaline and norepinephrine. Lastly, maprotiline is a strong inhibitor of the histamine H 1 receptor, which explains its sedative actions.

Maprotiline and Peginesatide fdating metabolites may be detected in the lungs, liver, brain, and kidneys; lower concentrations may be found in the adrenal glands, heart and muscle. Maprotiline is readily distributed into breast milk to similar concentrations as those in maternal blood. Maprotiline is metabolized by N -demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives.

It is slowly metabolized primarily to desmethylmaprotiline, a pharmacologically active metabolite. Desmethylmaprotiline may undergo further metabolism to maprotiline- N -oxide.

Drug created on June 13, Maprotiline Targets 13 Enzymes 2 Carriers 1 Biointeractions Drug Interaction R -warfarin The metabolism of R -warfarin can be decreased when combined with Maprotiline.

Clinical studies dating back to...

S -Warfarin The risk or severity of adverse effects can be increased when Peginesatide fdating is combined with S -Warfarin. Abacavir Maprotiline may decrease the excretion rate of Abacavir which could result in a higher serum level.

Abexinostat The risk or severity of QTc prolongation can be Peginesatide fdating when Maprotiline is combined with Abexinostat. Abiraterone The serum concentration of Maprotiline can be increased when it is combined with Abiraterone.

Acarbose Acarbose may decrease the excretion rate of Maprotiline which could result in a higher serum level. Acebutolol The risk or severity of QTc prolongation can be increased "Peginesatide fdating" Maprotiline is combined with Acebutolol.

Aceclofenac Aceclofenac may decrease the excretion rate of Maprotiline which could result in a higher serum level. Acefylline The serum concentration of Acefylline can be increased when Peginesatide fdating is combined with Maprotiline. Acemetacin Acemetacin may decrease the excretion rate of Maprotiline which could result in a higher serum level.

Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Maprotiline.

that peginesatide is non-inferior to...

Acepromazine The risk or severity of adverse effects can be increased when Maprotiline is combined with Acepromazine. Aceprometazine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Aceprometazine. Acetaminophen The metabolism of Maprotiline can be decreased when combined with Acetaminophen. Acetazolamide The risk Peginesatide fdating severity of adverse effects can be increased when Acetazolamide is combined with Maprotiline.

Acetophenazine The risk or severity of adverse effects can be increased when Maprotiline is combined with Acetophenazine. Acetyldigoxin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Acetyldigoxin. Acetylglycinamide chloral hydrate The risk or severity of adverse effects can be increased when Maprotiline is combined with Acetylglycinamide chloral hydrate. Peginesatide fdating acid Acetylsalicylic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.

Aclidinium The risk or severity of adverse effects can be increased when Maprotiline "Peginesatide fdating" combined with Aclidinium. Acrivastine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Peginesatide fdating. Acyclovir Acyclovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.

Adefovir Adefovir may decrease the Peginesatide fdating rate of Maprotiline which could result in a higher serum level. Adefovir Dipivoxil Adefovir Dipivoxil may decrease the excretion rate of Maprotiline which could result in a higher serum level. Adenosine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Adenosine. Adinazolam The risk or severity of adverse effects can be increased when Adinazolam is combined with Maprotiline. Adipiplon The risk or Peginesatide fdating of adverse effects can be increased when Maprotiline is combined with Adipiplon.

Agmatine The risk or severity of adverse effects can be increased when Maprotiline is combined with Agmatine.

Agomelatine The risk or severity of adverse effects can be increased when Maprotiline is combined with Agomelatine. Ajmaline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ajmaline. Ajulemic acid The risk or severity of Tachycardia and drowsiness can be increased when Peginesatide fdating is combined with Ajulemic acid.

Alaproclate The risk or severity of adverse effects can be increased when Maprotiline is combined with Alaproclate. Albendazole The metabolism of Maprotiline can be increased when combined with Albendazole. Albutrepenonacog alfa Maprotiline may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum Peginesatide fdating.

Alclofenac Alclofenac may decrease the excretion rate of Peginesatide fdating which could result in a higher serum level. Alcuronium The risk or severity of adverse effects can be increased when Maprotiline is combined with Alcuronium. Aldesleukin Aldesleukin may decrease the excretion rate of Maprotiline which could result in a higher serum level.

Alfaxalone The risk or severity of adverse effects can be increased when Maprotiline is combined with Alfaxalone. Alfentanil The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Maprotiline. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Maprotiline. Alimemazine The risk or severity of adverse effects can be increased when Maprotiline Peginesatide fdating combined with Alimemazine.

Allobarbital Peginesatide fdating risk or severity of adverse effects can be increased when Maprotiline is combined with Allobarbital.